Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors

ABSTRACT: Data contains results of LC-MS/MS analysis of KRAS4B-Q61H tyrosine phosphorylation following in vitro kinase reaction with Src kinase. Protein was denatured, reduced and alkylated and digested with Trypsin/Lys-C.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Brian Raught

PROVIDER: MSV000084657 | MassIVE | Wed Dec 04 08:16:00 GMT 2019

SECONDARY ACCESSION(S): PXD016608

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors.

Project description:Cancer cells bearing distinct KRAS mutations exhibit variable sensitivity to SHP2 inhibitors (SHP2i). Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i, and investigate the underlying mechanisms using biophysics, molecular dynamics, and cell-based approaches. Q61H mutation impairs intrinsic and GAP-mediated GTP hydrolysis, and impedes activation by SOS1, but does not alter tyrosyl phosphorylation. Wild-type and Q61H-mutant KRAS are both phosphorylated by Src on Tyr32 and Tyr64 and dephosphorylated by SHP2, however, SHP2i does not reduce ERK phosphorylation in KRAS Q61H cells. Phosphorylation of wild-type and Gly12-mutant KRAS, which are associated with sensitivity to SHP2i, confers resistance to regulation by GAP and GEF activities and impairs binding to RAF, whereas the near-complete GAP/GEF-resistance of KRAS Q61H remains unaltered, and high-affinity RAF interaction is retained. SHP2 can stimulate KRAS signaling by modulating GEF/GAP activities and dephosphorylating KRAS, processes that fail to regulate signaling of the Q61H mutant.

| S-EPMC8560773 | biostudies-literature

Bead-based kinase phosphorylation profiling identifies SRC as a therapeutic target in glioblastoma

Project description:Here we describe a bead-based method capable of profiling tyrosine kinase phosphorylations in a multiplexed, high-throughput and low-cost manner. This approach allows for the discovery of tyrosine kinase-activating events, even when the DNA sequence is wild-type. In an effort to pilot the establishment of a tyrosine kinase activation catalog, we profiled tyrosine phosphorylation levels of 62 tyrosine kinases in 130 human cancer lines, and followed-up on the frequent SRC phosphorylation in glioblastoma. Keywords: quantitative measurements of tyrosine phosphorylation levels on tyrosine kinases Total protein lysates were collected from 130 cancer cell lines. Tyrosine phosphorylation levels on 62 tyrosine kinases were measured with the bead assay.

2010-06-24 | E-GEOD-13808 | biostudies-arrayexpress

Regulation of Src tumor activity by its N-terminal intrinsically disordered region

Project description:The membrane anchored Src tyrosine kinase is involved in numerous pathways and its deregulation is involved in human cancer. Our knowledge on Src regulation relies on crystallography, which revealed intramolecular interactions to control active Src conformations. However, Src contains a N-terminal intrinsically disordered unique domain (UD) whose function remains unclear. Using NMR, we reported that UD forms an intramolecular fuzzy complex involving a conserved region with lipid-binding capacity named Unique Lipid Binding Region (ULBR), which could modulate Src membrane anchoring. Here we show that the ULBR is essential for Src’s oncogenic capacity. ULBR inactive mutations inhibited Src transforming activity in NIH3T3 cells and in human colon cancer cells. It also reduced Src-induced tumor development in nude mice. An intact ULBR was required for MAPK signaling without affecting Src kinase activity nor sub-cellular localization. Phospho-proteomic analyses revealed that, while not impacting on the global tyrosine phospho-proteome in colon cancer cells, this region modulates phosphorylation of specific membrane-localized tyrosine kinases needed for Src oncogenic signaling, including EPHA2 and Fyn. Collectively, this study reveals an important role of this intrinsically disordered region in malignant cell transformation and suggests a novel layer of Src regulation by this unique region via membrane substrate phosphorylation.

2022-01-14 | PXD030006 | Pride

Bead-based kinase phosphorylation profiling identifies SRC as a therapeutic target in glioblastoma

2008-12-05 | GSE13808 | GEO

Expression data from c-Src inhibited osteoblasts

2013-12-20 | GSE34570 | GEO

Expression data from c-Src inhibited osteoblasts

Project description:The tyrosine kinase c-Src has a crucial role in maintaining osteoblast in a less differentiated status, as already described in the literature. We used microarrays to detail the global programme of gene expression in osteoblasts treated with a well known c-Src inhibitor (PP1). Osteoblast primary cultures were isolated from calvaria of 7 days-old CD1 mice. These cell were starved and treated with vehicle (DMSO) or 2 micromolar PP1 for 24 hours. Then RNA was extracted and hybridizated on Affymetrix microarray.

2013-12-20 | E-GEOD-34570 | biostudies-arrayexpress

Novel treatment of human pancreatic cancer using masitinib combined with standard gemcitabine chemotherapy

Project description:Masitinib is a tyrosine kinase inhibitor of c-Kit, PDGFRα and β, and to some extent Lyn of the Src kinase family. We evaluated the therapeutic potential of masitinib in vitro on human pancreatic tumour cell lines and in vivo in a mouse model of human pancreatic cancer.

2009-09-05 | GSE17987 | GEO

Histologic transformation induced by EGFR tyrosine kinase inhibitors

Project description:Histologic transformation induced by EGFR tyrosine kinase inhibitors

| PRJNA1145888 | ENA

Genome-wide localization of SMAD2/3 and JUN family protein and epigenetic landscapes in human breast cell line treated with or without TGF-β.

Project description:The non-receptor tyrosine kinase SRC is overexpressed in various human cancers, however, transcriptional mechanisms underlying SRC expression is poorly understood. In this study, we found that transforming growth factor-β (TGF-β), which is abundantly secreted in tumor microenvironment, upregulates SRC protein and mRNA expression. To clarify the molecular mechanisms underlying TGF-β-induced SRC expression, we analyzed the genome-wide localization of SMAD2/3 and JUN family protein and epigenetic landscapes in human breast cell lines. These results showed that a novel TGF-β-responsive enhancer, which localizes at intragenic region of SRC, is activated via TGF-β/SMAD pathway and upregulates SRC expression.

2023-07-14 | GSE216432 | GEO

Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology: Phosphoproteomics

Project description:Multiple tyrosine kinase inhibitors (TKIs) are often developed for the same indication. However, their relative overall efficacy is frequently incompletely understood and they may harbor unrecognized targets that cooperate with the intended target. We compared several ROS1 TKIs for inhibition of ROS1-fusion-positive lung cancer cell viability, ROS1 autophosphorylation and kinase activity, which indicated disproportionately higher cellular potency of one TKI, lorlatinib. Quantitative chemical and phosphoproteomics across four ROS1 TKIs and differential network analysis revealed that lorlatinib uniquely impacted focal adhesion signaling. Functional validation using kinase assays, pharmacological probes and RNA interference uncovered a polypharmacology mechanism of lorlatinib by dual targeting ROS1 and PYK2, which form a multiprotein complex with SRC. Rational multi-targeting of this complex by combining lorlatinib with SRC inhibitors exhibited pronounced synergy. Taken together, we show that systems pharmacology-based differential network analysis can dissect mixed canonical/non-canonical polypharmacology mechanisms across multiple TKIs enabling the design of rational drug combinations.

2024-04-05 | PXD031359 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data